Literature DB >> 35962393

Correction: Pay-for-performance and continuity of care synergistically reduced amputation of lower extremity in patients with diabetes: a population-based cohort study.

Yu-Ching Chen1,2, Yi-Han Liao1, Li-Jung Elizabeth Ku3, Jung-Der Wang1,4.   

Abstract

Entities:  

Year:  2022        PMID: 35962393      PMCID: PMC9373327          DOI: 10.1186/s12913-022-08368-6

Source DB:  PubMed          Journal:  BMC Health Serv Res        ISSN: 1472-6963            Impact factor:   2.908


× No keyword cloud information.
Correction: BMC Health Serv Res 22, 748 (2022) https://doi.org/10.1186/s12913-022-08075-2 Following publication of the original article [1], some numbers under the heading P4P & COCI in Table 2 needs to be moved from the column Model A to the column Model B. This problem is caused due to a typesetting error. The correct Table 2 is given below.
Table 2

Adjusted hazard ratios by Cox proportional hazard model for different risk factors of LEA

CovariateAdjusted HR (95%CI)Adjusted HR (95% CI)Adjusted HR (95% CI)
Model AaModel BbModel Cc
P4P (ref.: non-P4P)0.35 (0.29-0.41)*0.37 (0.30-0.44)*
COCI0.08 (0.06-0.10)*
 Low COCI (reference)
 Middle COCI0.49 (0.43-0.55)*
 High COCI0.23 (0.21-0.27)*
P4P & COCI
 non-P4P, low COCI (reference)
 non-P4P, middle COCI0.68 (0.61-0.76)*
 non-P4P, high COCI0.26 (0.22-0.31)*
 P4P, low COCI0.53 (0.44-0.67)*
 P4P, middle COCI0.30 (0.23-0.38)*
 P4P, high COCI0.06 (0.04-0.10)*
Gender (ref.: female)
 Male1.16 (1.04-1.29) ǂ1.09 (0.99-1.20)1.15 (1.02-1.29)+
Age (ref.: 18< yr ≤ 55)
 56 ≤ yr ≤ 690.85 (0.73-1.00)+0.81 (0.70-0.94) ǂ0.89 (0.75-1.06)
 yr ≥ 700.71 (0.60-0.83)*0.59 (0.51-0.69)*0.73 (0.61-0.87)*
Diabetes duration (ref.: <5 yr)
 5 ≤ duration <102.06 (1.54-2.76)2.29 (1.76-2.98)*2.09 (1.52-2.87)*
 duration≥ 103.91 (2.93-5.20)4.35 (3.36-5.63)*3.90 (2.85-5.32)*
CCI score (ref: score=0)
 1-20.55 (0.47-0.64)*0.56 (0.48-0.64)*0.55 (0.47-0.66)*
 ≥ 30.28 (0.21-0.39)*0.31 (0.24-0.41)*0.30 (0.21-0.41)*
DSCI score (ref: score=0)
 1-21.07 (0.89-1.29)1.05 (0.89-1.24)1.11 (0.91-1.35)
 ≥ 31.77 (1.28-2.45)*1.63 (1.21-2.19) ǂ1.89 (1.34-2.65)*
CDD (ref: No)
 Yes0.72 (0.56-0.93)+0.82 (0.65-1.05)0.77 (0.58-1.01)
Residence (ref.: Rural)
 Urban0.82 (0.73-0.92)*0.81 (0.73-0.91)*0.83 (0.73-0.94) ǂ
Monthly salary/wage (ref.: FP and dependent)
 < NTD 20,0000.96 (0.83-1.10)0.96 (0.84-1.09)1.00 (0.86-1.15)
 ≥ NTD 20,0000.85 (0.75-0.97)+0.86 (0.76-0.96) ǂ0.91 (0.80-1.04)
Health care facility level (ref.: Medical center)
 Regional hospital1.14 (1.00-1.31)1.11 (0.98-1.26)1.13 (0.98-1.31)
 District hospital1.06 (0.92-1.23)1.02 (0.89-1.17)0.99 (0.83-1.16)
 Community clinic0.87 (0.75-1.01)0.86 (0.75-0.99) +0.89 (0.75-1.05)
Akaike information criterion30,78736,80430,699
Schwarz-Bayesian criterion30,88836,91830,794

*p<0.001; ǂ p<0.01; + p<0.05

a Categorical time-dependent time-weighted average COCI, b Stratification of average time weightedaverage COCI by P4P, c Continuous time-weighted average COCI, ref Reference, TWA Time-weighted average, P4P Pay for performance, COCI Continuity of care index, Int Intermediate COCI, CCI Charlson comorbidity index, DSCI Diabetes severity comorbidity index, CDD Catastrophic disabling disease, FP Fixed premium

Adjusted hazard ratios by Cox proportional hazard model for different risk factors of LEA *p<0.001; ǂ p<0.01; + p<0.05 a Categorical time-dependent time-weighted average COCI, b Stratification of average time weightedaverage COCI by P4P, c Continuous time-weighted average COCI, ref Reference, TWA Time-weighted average, P4P Pay for performance, COCI Continuity of care index, Int Intermediate COCI, CCI Charlson comorbidity index, DSCI Diabetes severity comorbidity index, CDD Catastrophic disabling disease, FP Fixed premium In calculating the cut-off points of tertiles for time-weighted average COCI 2010-2013, there was an error made in reporting so that the tertiles of the distribution of the COCI scores and thus the cutoffs should be corrected as follows: “low COCI (< 0.360)” revised to (<0.50); “middle COCI (0.360–0.643)” revised to (0.50-0.80); “high COCI (≥ 0.643)” revised to (≥0.80). Numbers to be revised are shown in the following 4 sections: Page 1, Abstract, Results: With the low COCI (<0.50) group as the reference, the aHR of LEA was 0.49 (p < 0.0001) for the middle COCI group, (p < 0.0001), and the aHR of LEA for the high COCI (≥0.80) group was 0.23 (p < 0.0001). Page 3, Line 2: We divided the COCI scores into 3 subgroups based on the tertiles of the distribution for analysis: low (<0.50), middle (0.50-0.80), and high (≥0.80). Page 8, Left column, Line 9-12: With the low COCI (<0.50) group as the reference, the aHR of LEA was 0.49 (p < 0.0001) for the middle COCI group, p < 0.0001, and the aHR of LEA for the high COCI (≥0.80) group was 0.23 (p < 0.0001). Page 8, Right column, Line 4-8 In model B, with low COCI (<0.50) subgroup of non-P4P group as the reference, the aHR of LEA was 0.68 (p < 0.0001) for middle COCI subgroup of non-P4P group, 0.26 (p < 0.0001) for high COCI (≥0.80) … The original article [1] has been corrected.

Page 1, Abstract, Results:

With the low COCI (<0.50) group as the reference, the aHR of LEA was 0.49 (p < 0.0001) for the middle COCI group, (p < 0.0001), and the aHR of LEA for the high COCI (≥0.80) group was 0.23 (p < 0.0001).

Page 3, Line 2:

We divided the COCI scores into 3 subgroups based on the tertiles of the distribution for analysis: low (<0.50), middle (0.50-0.80), and high (≥0.80).

Page 8, Left column, Line 9-12:

With the low COCI (<0.50) group as the reference, the aHR of LEA was 0.49 (p < 0.0001) for the middle COCI group, p < 0.0001, and the aHR of LEA for the high COCI (≥0.80) group was 0.23 (p < 0.0001).

Page 8, Right column, Line 4-8

In model B, with low COCI (<0.50) subgroup of non-P4P group as the reference, the aHR of LEA was 0.68 (p < 0.0001) for middle COCI subgroup of non-P4P group, 0.26 (p < 0.0001) for high COCI (≥0.80) …

  1 in total

1.  Pay-for-performance and continuity of care synergistically reduced amputation of lower extremity in patients with diabetes: a population-based cohort study.

Authors:  Yu-Ching Chen; Yi-Han Liao; Li-Jung Elizabeth Ku; Jung-Der Wang
Journal:  BMC Health Serv Res       Date:  2022-06-04       Impact factor: 2.908

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.